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Background: Mutations in KIT and fms-like tyrosine kinase 3 genes lead to uncontrolled 
proliferation of leukemic cells with a poor prognosis. Since, data concerning the incidence and 
associations with patients characteristics vary amongst different studies, the aim of the present 
study is to identify and quantify the frequency of mutations in Iranian patients suffering from acute 
myeloid leukemia.  
Methods: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 
gene of acute myeloid leukemia patients were studied through polymerase chain reaction and 
polymerase chain reaction-RFLP analysis. Amplified products for a point mutation in D816 for KIT 
have also been identified through the polymerase chain reaction-RFLP technique. The mutations in 
exon 8 of KIT were detected by using the PCR and the Conformational Sensitive Gel 
Electrophoresis techniques, and amplified products have been confirmed by sequencing 
techniques. 
Results: Internal tandem duplication and D835 mutations in the fms-like tyrosine kinase 3 gene 
occurred in 18% and 6% of AML patients, respectively. Frequencies of mutation were 1.4% and 
4.7% in exon 8 and D816 of the KIT gene in acute myeloid leukemia patients. These results were 
substantially different for various subclasses of French-American-British classification. 
Conclusion: This study revealed that approximately 30% of acute myeloid leukemia patients 
have either KIT or fms-like tyrosine kinase 3 genetic mutations. The presence of fms-like tyrosine 
kinase 3 was significantly associated with M3 morphology and mutations of KIT were significantly 
associated with M2 and M4 subtypes.   
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Introduction 
 
mongst various factors, mutations for 
cell differentiation and proliferation are 
considered to be effective factors in the 
development of acute myeloid leukemia (AML).  
fms-like tyrosine kinase 3 (FLT3) and KIT genes 
belong to the family of tyrosine kinase class III 
receptors that induce signals for cell proliferation. 
Mutations of these genes, however, result in 
autonomously leukemic cell proliferation and an 
unfavorable prognosis.1–3  
A significant over expression of the FLT3 gene 
(70 – 100%) occurs in both AML and acute 
lymphoblastic leukemia (ALL)4–6 and point 
mutations in both the D835 and internal tandem 
duplication (ITD) of this gene occur as main 
mutations. These mutations lead to a steady and 
continual activation of the FLT3 tyrosine kinase 
receptor without ligand stimulation.7,8 The ITD 
mutation is the most frequent abnormality that 
occurs in 20 – 25% of AML patients and the D835 
point mutation has been identified in 6 – 10% of 
patients.9–12 The augmented activation of KIT with 
SCF causes cell proliferation whereby in AML, an 
abnormal increase of proliferation occurs in two 
ways; first in AML, mutations of D816 (in exon 
17) or exon 8 KIT lead to autonomous activation 
of KIT, and also through over expression of KIT in 
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AML when  KIT is expressed in 80 – 90% of blast 
cells.13,14 Generally KIT mutations have been 
reported in less than 5% of AML cases.15 The poor 
prognosis in AML patients with mutations in the 
KIT and FLT3 genes, has led to the development 
of drugs inhibiting these mutations.16–18 Due to 
insufficient studies of the mutations in Iran, the 
diagnosis and frequency of these mutations with 
different subtypes in AML patients is an important 
concern. 
 
Materials and Methods 
 
Patients 
Blood samples from 212 adult AML patients 
with various French-American-British (FAB) 
classifications were obtained from Iranian 
hematologic and blood transfusion centers between 
2006 and 2007. The diagnosis of AML and the 
assignment of FAB classification were based on 
morphology and immunophenotype. 
 
Molecular studies 
DNA extraction was performed on all blood 
samples by the proteinase K and phenol methods.19  
 
Analysis of ITD of the FLT3 gene and D835 
mutations  
FLT3-ITD and FLT3-D835 mutations were 
amplified using PCR (Corbett Research) and 
products were electrophoresed on an 8% 
polyacrylamide gel as previously described by 
Gilliand et al.12 To detect ITD, exons 11 and 12 
were amplified by PCR using primers 11F (5'-
GCA ATT TAG GTA TGA AAG CCA GC-3'), 
and 12R (5'-CTT TCA GCA TTT TGA CGG CAA 
CC-3'). To detect D835, exon 17 was amplified by 
PCR using primers 17F (5'-CCG CCA GGA ACG 
TGC TTG-3'), and 17R (5'-GCA GCC TCA CAT 
TGC CCC-3'). Finally, PCR products were 
digested with the EcoRV enzyme.20,21 
 
KIT mutational analysis 
The Conformational Sensitive Gel 
Electrophoresis (CSGE) method was used to 
screen for mutations in exon 8 of the KIT gene as 
described previously by Gari et al.22 Briefly, PCR 
was performed using primers 8F (5'-
TTCTGCCCTTTGAACTTGCT-3') and 8R (5'- 
AAAGCCACATGGCTAGAAAAA-3') as previ-
ously described by Rapley et al.23 PCR products 
were denatured by heating at 95°C for 5 minutes 
and then incubated at 65ºC for 30 minutes. These 
heteroduplexed products were then electrophoresed 
on a 10% polyacrylamide gel consisting of 99:1 
acrylamide:BAP (bis-acrolypiperazine), 10% 
ethylene glycol, 15% formamide and 0.5x TTE 
buffer (tris, taurine, and EDTA). Samples 
displaying abnormal CSGE profiles were directly 
sequenced by an automated sequencing machine to 
confirm the presence of the mutation. To detect 
KIT-D816, exon 17 amplified by PCR using 
primers 17F (5'-TGT ATT CAC AGA GAC TTG 
GCA-3') and 17R (5'-TAA TTA GAA TCA TTC 
TTG ACG-3'). Then, PCR products were digested 
with AatII enzyme as described by Looijenga  
et al.24 
 
Results 
 
The median age of onset for AML was 4712 
(range from18 – 75) years, and blood samples from 
126 males and 86 females were included in the 
study.   
 
Mutational analysis of FLT3 
The ITD mutation was observed in 18% of 
AML patients.  In Figure 1, lanes 1 and 3 
represented patient specimens with an AML M3 
subtype that had a mutation.  Lanes 9 and 14 
represented AML patients with M2 and M4 
subtypes. In all cases, small bands (329 bp) have 
represented normal cell clones and larger bands 
were mutated leukemic cell clones. To detect a 
D835 mutation, exon 17 of FLT3 has been 
amplified by PCR and then digested with ECORV 
enzyme (Figure 2). The 114 bp products were 
shown to be separated into 68 bp and 46 bp with 
no mutation in the sequences. Patients 5 and 13 
produced  different  bands in which the upper band  
with 114 bp has a changed enzyme restriction site 
due to a mutation and the lower band with 68 bp 
and 46 bp represented genes of a normal cell clone 
Figure 1. ITD mutations in different subgroups of 
AML patients (N=negative control, M=marker)  
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in the AML patient. Overall, the present study 
indicated that in 18% of the ITD mutations; 16% 
have been found in the M3 subclass and the 
remainder belong to both M2 and M4 subclasses. 
Furthermore, of the 6% with mutations in D835; 
4% were located in the M3 subclass and the rest in 
both M2 and M5 subclasses.  
 
Mutational analysis of KIT 
Of the 212 AML patients investigated in this 
study, three patients' specimens had mutations in 
exon 8. Figure 3 demonstrates lanes 7, 11, and 13 
that relate to patients M4, M2 and M4, each of 
them had 3 different bands. The remainder show 
one band which represented a wild type with 386 
bp. In addition, genomic sequencing confirmed 
insertion and deletion sequences in exon 8 in two 
patients' samples but the third sample was failed. 
These new mutations have been submitted and 
documented in the Gene Bank (FJ177639 and 
FJ189474). In one case, the fragment 
GACAGGCT has been deleted and TGGCA was 
inserted. In the other case, however, only the 
GACAGGCTT fragment has been inserted without 
any  deletion. Of all patients studied, samples from 
ten patients were shown to have a point mutation at 
D816. The AatII enzyme was capable of 
identifying the sequence present in the wild type of 
KIT and hence the 106 bp PCR products were 
spliced into 85 bp and 21 bp, which this enzymatic 
DNA analysis would not occur if a mutation was 
present at D816. While the 85bp band was 
detectable, the 21bp band ran off the gel. In Figure 
4, the D816 mutation has occurred in columns 4, 5, 
and 8. Due to sequence alteration at the breaking 
point, the 106 bp nucleotides have not been 
digested. In general, out of 212 AML patients, 3 
(1.4%) contain exon 8 mutations and 10 (4.7%) 
have D816 point mutations in the KIT gene.  One 
of the M2 samples had mutations in both exon 8 
and D816. These mutations were typically located 
within the M2 and M4 subclasses, whereas only 
one case of M1 had a D816 mutation. 
 
Discussion  
 
Mutations of both the KIT and FLT3 genes 
have a great impact on leukemia pathogenesis, 
most specifically on patients who suffer from 
AML. Mutations also lead to uncontrolled 
proliferation of leukemic cells. Despite the 
pathogenic effect of these mutations, they are not 
the sole cause of acute leukemia, which may 
require other genomic alterations related to cell 
differentiation. These mutations are usually 
associated with a poor prognosis.25–28 
 In this study of adults with AML, a total of 
24% mutations were observed in the FLT3 gene of 
which 18% were ITD that mostly occurred in the 
M3 subclass which was characterized by the T.15–17 
No positive cases of ITD mutation were observed 
in patient specimens within the M0, M1, and M5 
subclasses. Evidence to date has suggested that 
PML/RARA gene fusion is not sufficient for 
Figure 2. D835 mutations in different subgroups of 
AML patients (N=negative control, M=marker) 
Figure 3. Exon 8 mutations in different subgroups of 
AML patients (M=marker)  
 
Figure 4. D816 mutations in different subgroups of 
AML patients (M=marker)  
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leukomogenesis. Other factors such as mutations 
of FLT3 could also confer a proliferative 
advantage hence halting the differentiation 
process.20,26,27 Various studies have reported a high 
occurrence of ITD in 385 of 1595 of adult patients 
(24%) with AML and another study has shown that 
ITD mutations occur in 20 to 30% of AML cases 
and D835 occurs in 7 to 10% of patients.21,29 ITD 
has mostly been observed within AML M3 
samples and the least occurrence within AML M2 
samples.20,29 However, other studies have reported 
an irregular occurrence of mutations among the 
subclasses.25,28 In this study, most FLT3 mutations 
have been observed within M3 subclasses. The 
second most abundant FLT3 mutation occurred in 
D835 of this gene which has been identified within 
6% of our patient samples, but it was not detected 
in people with M1, M0, and M4 subclasses. The 
D835 substitution has been reported in 30 out of 
429 cases (7%) of AML, in 1 out of 29 cases (3%) 
of MDS and in 1 out of 36 cases (3%) of ALL.21,30 
There are a few reports about the involvement 
of c-KIT mutations (exon 8 and 17) in AML 
patients, of which these mutations are not a rare 
event in core binding factor (CBF) leukemia.3,25 In 
AML patients that were investigated in this study, 
the mutation of exon 8 KIT gene has occurred in 
1.2% of M2 cases, 3.7% of M4 cases, and in 1.4% 
of total cases. Most mutations and alteration in 
sequences were detected in the KIT gene when 
exon 17 in this gene was analyzed. This mutation 
is a point mutation in which the aspartic amino 
acid in the 816 (D816) locus is substituted with 
other amino acids, leading to loop activation.31,32 In 
the present work, the D816 mutation occurred in 
3.7% of the M1, 9.8% of M2, and 1.8% of the M4 
subclasses as well as 4.7% of total cases with 
AML, whereas the frequency of mutations in the 
previous study were 0.9%, 3.1%, 1.8%, and 1.7%, 
respectively.33 Therefore the frequency of the 
D816 mutation has been shown to be more than 
reported in the past. Ethnicity may strongly 
influence the frequency of the reported mutated 
gene. Out of all the studied patients, one patient 
with an M2 subtype had both exon 8 and D816 
mutations, hence harboring 5.6% of the KIT 
mutation.  
 
Conclusion 
 
In this study we demonstrated that FLT3 
mutations are frequent molecular abnormalities in 
AML patients with an incidence of 24%. The 
presence of ITD was significantly associated with 
M3 morphology. Mutations of c-KIT resulted in 
5.6% of AML (one patient had both mutations 
together) that was significantly associated with M2 
and M4 subtypes. These data show that 
approximately one third of AML patients had 
mutations in the tyrosine kinase receptor. Although 
our data do not support its value as a prognostic 
factor in AML patients, further investigation is 
required.  
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